Zimmer Biomet (NYSE:ZBH – Get Free Report) had its price objective increased by analysts at Citigroup from $99.00 to $117.00 in a research report issued on Thursday, Benzinga reports. The brokerage currently has a “neutral” rating on the medical equipment provider’s stock. Citigroup‘s price target suggests a potential upside of 9.27% from the stock’s previous close.
A number of other analysts also recently commented on the company. Wells Fargo & Company boosted their target price on Zimmer Biomet from $103.00 to $113.00 and gave the stock an “equal weight” rating in a research report on Thursday. Zacks Research upgraded Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 25th. Truist Financial lifted their price target on Zimmer Biomet from $92.00 to $106.00 and gave the stock a “hold” rating in a research note on Thursday, August 6th. Canaccord Genuity Group boosted their price objective on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a research report on Monday, August 10th. Finally, UBS Group reissued a “buy” rating and set a $120.00 price target on shares of Zimmer Biomet in a research report on Thursday, August 6th. Seven research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $109.68.
Get Our Latest Analysis on ZBH
Zimmer Biomet Price Performance
Shares of NYSE:ZBH traded down $3.07 during trading on Thursday, hitting $107.08. 3,623,454 shares of the stock were exchanged, compared to its average volume of 2,266,772. The company has a fifty day moving average price of $94.90 and a two-hundred day moving average price of $91.89. The company has a market cap of $20.42 billion, a PE ratio of 26.05, a P/E/G ratio of 2.33 and a beta of 0.50. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. Zimmer Biomet has a 12-month low of $79.12 and a 12-month high of $112.54.
Zimmer Biomet (NYSE:ZBH – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The business had revenue of $2.06 billion for the quarter, compared to analysts’ expectations of $2.04 billion. During the same quarter in the prior year, the firm posted $1.90 EPS. The company’s revenue was up 3.1% compared to the same quarter last year. On average, analysts forecast that Zimmer Biomet will post 8.54 EPS for the current year.
Insider Buying and Selling
In related news, insider Kevin R. Thornal sold 5,691 shares of the stock in a transaction on Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Chad F. Phipps sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the sale, the insider owned 65,231 shares in the company, valued at approximately $6,415,468.85. The trade was a 4.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.28% of the company’s stock.
Hedge Funds Weigh In On Zimmer Biomet
Institutional investors have recently added to or reduced their stakes in the company. OMERS ADMINISTRATION Corp acquired a new position in shares of Zimmer Biomet in the second quarter worth about $922,000. Hsbc Holdings PLC acquired a new position in Zimmer Biomet in the second quarter worth $35,417,000. Nykredit A S bought a new stake in shares of Zimmer Biomet during the 2nd quarter valued at about $3,419,000. Legal & General Group Plc bought a new position in shares of Zimmer Biomet during the second quarter valued at approximately $126,167,000. Finally, Rakuten Investment Management Inc. bought a new position in Zimmer Biomet during the 2nd quarter worth $2,945,000. Institutional investors and hedge funds own 88.89% of the company’s stock.
Trending Headlines about Zimmer Biomet
Here are the key news stories impacting Zimmer Biomet this week:
- Positive Sentiment: Zimmer Biomet beat third-quarter estimates, with adjusted EPS of $1.90 and revenue of $2.063 billion, up 3.1% year over year. The company also raised its full-year 2026 outlook; strong hip and sports medicine sales helped offset a weaker knee market. Zimmer Biomet Announces Third Quarter 2026 Financial Results
- Positive Sentiment: Royal Bank of Canada raised its price target from $110 to $125 and maintained an outperform rating, signaling greater potential upside in the shares. Royal Bank of Canada recommendations
- Positive Sentiment: The CEO said the company is not seeing a slowdown in orthopedic procedures, which may support continued demand for its products. Zimmer Biomet CEO doesn’t see slowdown in ortho procedures
- Neutral Sentiment: Wells Fargo raised its target to $113 but kept an equal-weight rating; Bernstein lifted its target to $107 while maintaining market perform. The higher targets are tempered by those cautious-to-neutral ratings. Wells Fargo recommendations
- Negative Sentiment: Adjusted earnings were flat year over year, while reported diluted EPS fell 13.8%. Weakness in knees and margin pressure remain headwinds, even as other product categories supported sales growth. Zimmer Biomet Q3 Profit Falls, Lifts FY26 Outlook
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.
The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.
Read More
- Five stocks we like better than Zimmer Biomet
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.
